YS SC2 010
Alternative Names: PIKA recombinant COVID-19 vaccine; PIKA recombinant COVID-2019 vaccine; YS-SC2-010Latest Information Update: 22 Aug 2024
At a glance
- Originator Yisheng Biopharma
- Developer LakeShore Biopharma; Yisheng Biopharma
- Class COVID-19 vaccines; Protein vaccines; Subunit vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III COVID 2019 infections
Most Recent Events
- 22 Aug 2024 Preclinical trials in COVID-2019 infections (Prevention) in China (Inhalation), prior to August 2024 (YS Biopharma pipeline, August 2024)
- 22 Aug 2024 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral, Injection), prior to August 2024 (YS Biopharma pipeline, August 2024)
- 24 May 2024 YS Biopharma is now called LakeShore Biopharma